ES2745532T3 - Sobetirome en el tratamiento de enfermedades de mielinización - Google Patents

Sobetirome en el tratamiento de enfermedades de mielinización Download PDF

Info

Publication number
ES2745532T3
ES2745532T3 ES14791718T ES14791718T ES2745532T3 ES 2745532 T3 ES2745532 T3 ES 2745532T3 ES 14791718 T ES14791718 T ES 14791718T ES 14791718 T ES14791718 T ES 14791718T ES 2745532 T3 ES2745532 T3 ES 2745532T3
Authority
ES
Spain
Prior art keywords
sobetirome
disease
pharmaceutically acceptable
acceptable salt
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14791718T
Other languages
English (en)
Spanish (es)
Inventor
Meredith Hartley
Andrew Placzek
Marco Righi
Dennis Bourdette
Gail Marracci
Priya Chaudhary
Thomas S Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
US Department of Veterans Affairs
Original Assignee
Oregon Health and Science University
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University, US Department of Veterans Affairs filed Critical Oregon Health and Science University
Application granted granted Critical
Publication of ES2745532T3 publication Critical patent/ES2745532T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES14791718T 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización Active ES2745532T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
ES2745532T3 true ES2745532T3 (es) 2020-03-02

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14791718T Active ES2745532T3 (es) 2013-05-03 2014-02-05 Sobetirome en el tratamiento de enfermedades de mielinización

Country Status (12)

Country Link
US (3) US10226438B2 (cg-RX-API-DMAC7.html)
EP (1) EP2991670B8 (cg-RX-API-DMAC7.html)
JP (4) JP2016517883A (cg-RX-API-DMAC7.html)
CN (1) CN105431163A (cg-RX-API-DMAC7.html)
AU (1) AU2014260468A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015027682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2911309A1 (cg-RX-API-DMAC7.html)
ES (1) ES2745532T3 (cg-RX-API-DMAC7.html)
MX (2) MX379043B (cg-RX-API-DMAC7.html)
RU (1) RU2015151216A (cg-RX-API-DMAC7.html)
SG (2) SG10201709090UA (cg-RX-API-DMAC7.html)
WO (2) WO2014178892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
US20170119899A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
EP3445372A4 (en) * 2016-04-22 2020-03-25 Viking Therapeutics, Inc. USE OF THYROID BETA AGONISTS
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
LT3457851T (lt) 2016-05-18 2021-10-11 Oregon Health & Science University Sobetiromo dariniai
AU2017310535B2 (en) * 2016-08-12 2021-11-11 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
US11660281B2 (en) 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) * 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN113423684A (zh) 2018-12-12 2021-09-21 速通医疗公司 新型拟甲状腺素药
US11667606B2 (en) 2019-03-01 2023-06-06 Autobahn Therapeutics, Inc. Thyromimetics
MX2022006470A (es) 2019-11-29 2022-08-04 Autobahn Therapeutics Inc Tiromimeticos novedosos.
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
EP1003530A4 (en) 1996-08-20 2001-10-04 Univ California EYE TREATMENT USING SYNTHETIC THYROID HORMONE COMPOSITIONS
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
KR20010053277A (ko) 1998-06-30 2001-06-25 린다 에스. 스티븐슨 갑상선 호르몬 유사체 및 그 제조 방법
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1878545A (zh) * 2003-09-15 2006-12-13 奥德威研究院 甲状腺激素类似物及其使用方法
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
PL2187882T3 (pl) * 2007-07-11 2013-05-31 Medicinova Inc Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20160029870A (ko) * 2008-04-21 2016-03-15 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
JP6060268B2 (ja) * 2012-10-25 2017-01-11 ボルボ トラック コーポレイション 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
WO2014178892A8 (en) 2015-12-17
EP2991670A1 (en) 2016-03-09
SG10201709090UA (en) 2017-12-28
MX379043B (es) 2025-03-10
JP6360552B2 (ja) 2018-07-18
WO2014178892A1 (en) 2014-11-06
WO2014178931A1 (en) 2014-11-06
US10226438B2 (en) 2019-03-12
JP6360552B6 (ja) 2018-08-15
US11510887B2 (en) 2022-11-29
WO2014178931A8 (en) 2015-11-26
EP2991670B1 (en) 2019-07-03
CA2911309A1 (en) 2014-11-06
US20200405669A1 (en) 2020-12-31
JP2018162321A (ja) 2018-10-18
MX2015015228A (es) 2016-10-03
RU2015151216A (ru) 2017-06-08
AU2014260468A1 (en) 2015-11-19
US20190175531A1 (en) 2019-06-13
BR112015027682A2 (pt) 2017-08-29
US20160081955A1 (en) 2016-03-24
HK1222552A1 (en) 2017-07-07
EP2991670A4 (en) 2017-01-18
JP2016517883A (ja) 2016-06-20
JP2018141024A (ja) 2018-09-13
CN105431163A (zh) 2016-03-23
EP2991670B8 (en) 2019-09-11
JP2016517884A (ja) 2016-06-20
SG11201509012QA (en) 2015-11-27
MX2021000538A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
ES2745532T3 (es) Sobetirome en el tratamiento de enfermedades de mielinización
US10987333B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
KR20240057401A (ko) 파라잔틴-기반 카페인 대용 조성물 및 느린 카페인 대사자에서의 이의 사용 방법
ES2385702T3 (es) Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
CN106456606A (zh) 吲哚基及吲哚啉基异羟肟酸于治疗神经退化病症或认知缺乏的用途
WO2023101866A1 (en) Fenfluramine for treatment of conditions associated with spreading depolarization
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
CN104411308B (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
HK1222552B (en) Sobetirome in the treatment of myelination diseases
EP3388061A1 (en) Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
US20210369720A1 (en) Synergistic composition having neuroprotective properties and methods of use thereof
RU2345778C1 (ru) Способ лечения расстройств эрекции у мужчин
GB2547241A (en) Anti-inflammatory formulation
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
ES2575736T3 (es) Composición de extractos ricos en elagitaninos para el bienestar sexual
ES2946699A1 (es) Extracto de cerebro de cerdo y su uso en el tratamiento de enfermedades neurodegenerativas
ITUB20153895A1 (it) Associazione di curcumina, arginina e vitamina d
KR20160018806A (ko) 연하장애 개선용 의약품
Fedorov et al. COMPARATIVE ANALYSIS OF CLINICAL AND IMMUNOLOGICAL INDICATORS OF PHARMACOREISTITENIC PATIENTS WITH SCHIZOPHRENIA COMBODY WITH TUBERCULOSIS OF LUNGS WHEN PURPOSE OF FLUANXOL AND CYCLOPHERON
CA2944750A1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci